BUGDF: AI 评分 46/100 — AI 分析 (4月 2026)

Bumrungrad Hospital Public Company Limited operates a leading medical center in Thailand, providing a wide range of diagnostic, therapeutic, and intensive care services to both domestic and international patients. With a strong focus on quality and innovation, the company aims to maintain its position as a premier healthcare provider in Southeast Asia.

Key Facts: AI Score: 46/100 Sector: Healthcare

公司概况

概要：

Bumrungrad Hospital Public Company Limited, based in Thailand, operates a comprehensive medical center offering diverse healthcare services, including specialized clinics and diagnostic facilities. With a focus on international patients and a high profit margin of 29.8%, the company distinguishes itself through its commitment to quality care and a wide range of medical specialties.

BUGDF是做什么的？

Founded in 1980 and headquartered in Bangkok, Thailand, Bumrungrad Hospital Public Company Limited has evolved into a leading healthcare provider in Southeast Asia. The company operates a 580-bed medical center with approximately 56 clinics and centers, offering a comprehensive range of medical services. These include diagnostic, therapeutic, and intensive care facilities, catering to both local and international patients. Bumrungrad's outpatient clinics and centers cover a wide spectrum of specialties, such as allergy, cardiology, oncology, orthopedics, and women's health. The hospital is also involved in real estate asset holding, clinical research services, and the distribution of pharmaceutical and medical goods through specialized stores. Bumrungrad has established itself as a premier destination for medical tourism, attracting patients from around the world seeking high-quality healthcare services. The company is committed to continuous improvement and innovation, investing in advanced medical technologies and fostering a culture of excellence among its healthcare professionals. Its focus on patient-centric care and international standards has contributed to its strong reputation and financial performance.

BUGDF的投资论点是什么？

Bumrungrad Hospital Public Company Limited presents a notable market position due to its strong market position, high profitability, and growth potential in the healthcare sector. The company's profit margin of 29.8% and gross margin of 51.8% indicate efficient operations and pricing power. The dividend yield of 2.82% offers an attractive income stream for investors. Growth catalysts include expanding medical tourism, increasing demand for specialized medical services, and strategic investments in new technologies and facilities. However, potential risks include competition from other healthcare providers, regulatory changes, and economic fluctuations affecting patient volumes. Bumrungrad's beta of -0.07 suggests low volatility compared to the overall market.

BUGDF在哪个行业运营？

Bumrungrad Hospital Public Company Limited operates within the growing healthcare industry, driven by factors such as aging populations, increasing prevalence of chronic diseases, and rising healthcare expenditure. The medical tourism market is a significant growth driver, with patients seeking high-quality and affordable healthcare services in countries like Thailand. The competitive landscape includes other private hospitals and medical centers, both domestic and international. Bumrungrad differentiates itself through its focus on international patients, comprehensive range of services, and commitment to quality and innovation. The healthcare industry is subject to regulatory oversight and technological advancements, requiring companies to adapt and invest in new capabilities.

Medical - Care Facilities

Healthcare

BUGDF有哪些增长机遇？

Expansion of Medical Tourism: Bumrungrad has a significant opportunity to further expand its medical tourism business by targeting new markets and offering specialized packages for international patients. The global medical tourism market is projected to reach $272.7 billion by 2027, growing at a CAGR of 12.8% from 2020. Bumrungrad can leverage its reputation for quality and its strategic location in Bangkok to attract more patients from Asia, the Middle East, and other regions. Timeline: Ongoing.
Development of Specialized Medical Centers: Bumrungrad can enhance its service offerings and attract more patients by developing specialized medical centers focused on specific areas such as oncology, cardiology, and orthopedics. These centers can offer advanced diagnostic and treatment options, attracting patients seeking specialized care. The market for specialized medical services is growing rapidly, driven by increasing prevalence of chronic diseases and advancements in medical technology. Timeline: Ongoing.
Investment in Digital Health Technologies: Bumrungrad can improve patient experience and operational efficiency by investing in digital health technologies such as telemedicine, remote monitoring, and electronic health records. These technologies can enable the company to provide more convenient and accessible healthcare services, attract younger patients, and reduce costs. The digital health market is expected to reach $660 billion by 2025, growing at a CAGR of 28.5% from 2020. Timeline: Ongoing.
Strategic Partnerships and Acquisitions: Bumrungrad can expand its geographic reach and service offerings through strategic partnerships and acquisitions. The company can partner with other healthcare providers, insurance companies, and technology companies to offer integrated healthcare solutions and reach new markets. Acquisitions can enable Bumrungrad to acquire new technologies, expand its service offerings, and increase its market share. Timeline: Ongoing.
Focus on Preventive Healthcare: Bumrungrad can capitalize on the growing demand for preventive healthcare services by offering health screening programs, wellness programs, and lifestyle coaching. These services can help patients prevent chronic diseases, improve their overall health, and reduce healthcare costs. The preventive healthcare market is expected to reach $432.3 billion by 2027, growing at a CAGR of 10.2% from 2020. Timeline: Ongoing.

Market capitalization of $3.78 billion reflects Bumrungrad's significant presence in the healthcare industry.
P/E ratio of 18.75 indicates a reasonable valuation compared to its earnings.
Profit margin of 29.8% demonstrates strong profitability and efficient cost management.
Gross margin of 51.8% highlights the company's ability to generate revenue from its services.
Dividend yield of 2.82% provides an attractive income stream for investors.

BUGDF提供哪些产品和服务？

Operates a 580-bed medical center in Bangkok, Thailand.
Provides diagnostic, therapeutic, and intensive care facilities.
Offers a wide range of outpatient clinics and centers covering various medical specialties.
Caters to both local and international patients.
Engages in real estate asset holding activities.
Provides clinical research services.
Distributes pharmaceutical and medical goods through specialized stores.
Operates a personnel development and training center for healthcare services.

BUGDF如何赚钱？

Generates revenue from providing medical services to patients.
Attracts international patients seeking high-quality and affordable healthcare.
Offers a comprehensive range of medical specialties and services.
Invests in advanced medical technologies and facilities.
Focuses on patient-centric care and international standards.

Local patients in Thailand seeking medical care.
International patients seeking medical tourism services.
Insurance companies and healthcare providers.
Corporate clients seeking employee health benefits.
Patients seeking specialized medical treatments and procedures.

Strong brand reputation and recognition in the healthcare industry.
Strategic location in Bangkok, a major hub for medical tourism.
Comprehensive range of medical services and specialties.
Focus on international patients and high-quality care.
Advanced medical technologies and facilities.

什么因素可能推动BUGDF股价上涨？

Ongoing: Expansion of medical tourism services targeting new international markets.
Ongoing: Development of specialized medical centers focused on high-demand areas like oncology and cardiology.
Ongoing: Investment in digital health technologies to improve patient experience and operational efficiency.
Upcoming: Potential strategic partnerships or acquisitions to expand geographic reach and service offerings.
Ongoing: Focus on preventive healthcare services to capitalize on the growing demand for wellness programs.

BUGDF的主要风险是什么？

Potential: Economic downturns could reduce patient volumes and impact revenue.
Potential: Political instability in Thailand could disrupt operations and deter medical tourists.
Potential: Outbreaks of infectious diseases could strain resources and reduce patient confidence.
Ongoing: Competition from other healthcare providers in Thailand and internationally.
Ongoing: Changes in healthcare regulations could increase compliance costs and affect profitability.

BUGDF的核心优势是什么？

Strong brand reputation and recognition.
Comprehensive range of medical services.
Strategic location for medical tourism.
High profit margin and financial performance.

BUGDF的劣势是什么？

Dependence on international patients.
Exposure to currency fluctuations.
Competition from other healthcare providers.
Regulatory risks in the healthcare industry.

BUGDF有哪些机遇？

Expansion of medical tourism business.
Development of specialized medical centers.
Investment in digital health technologies.
Strategic partnerships and acquisitions.

BUGDF面临哪些威胁？

Economic downturns affecting patient volumes.
Political instability in Thailand.
Outbreaks of infectious diseases.
Changes in healthcare regulations.

BUGDF的竞争对手是谁？

Apollo Medical Holdings, Inc. — Focuses on coordinated care and value-based healthcare models. — (AMBFF)
Aster DM Healthcare Ltd — Operates hospitals and clinics in the Middle East and India. — (AMFPF)
Mahindra Lifespace Developers Ltd — Primarily focused on real estate development, but has some healthcare-related projects. — (MAHLY)
Medical Properties Trust Inc — Real Estate Investment Trust that invests in healthcare facilities. — (MEPDF)
Nihon Healthcare Corp — Focuses on providing healthcare services and products in Japan. — (NHNKY)

Key Metrics

MoonshotScore: 46/100

Company Profile

CEO: Artirat Charukitpipat
Headquarters: Bangkok, TH
Founded: 2010

AI Insight

AI analysis pending for BUGDF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Bumrungrad Hospital Public Company Limited do?

Bumrungrad Hospital Public Company Limited operates a leading private hospital in Bangkok, Thailand, providing a comprehensive range of medical services to both local and international patients. The hospital offers diagnostic, therapeutic, and intensive care facilities, with specialized clinics and centers covering various medical specialties such as cardiology, oncology, orthopedics, and neurology. Bumrungrad focuses on attracting medical tourists by providing high-quality care, advanced medical technologies, and a patient-centric approach, making it a prominent player in the medical tourism industry.

What do analysts say about BUGDF stock?

Analyst coverage of BUGDF stock is limited due to its OTC listing. However, considering its strong market position in Thailand's healthcare sector, its focus on medical tourism, and its consistent profitability, analysts generally view Bumrungrad Hospital Public Company Limited as a stable and reliable company. Key valuation metrics such as P/E ratio and dividend yield suggest a reasonable valuation. Growth considerations include the expansion of medical tourism, strategic investments in new technologies, and the development of specialized medical centers. No buy/sell recommendations are being made.

What are the main risks for BUGDF?

The main risks for Bumrungrad Hospital Public Company Limited include economic downturns that could reduce patient volumes, political instability in Thailand that could deter medical tourists, and outbreaks of infectious diseases that could strain resources and reduce patient confidence. Competition from other healthcare providers in Thailand and internationally also poses a risk. Additionally, changes in healthcare regulations could increase compliance costs and affect profitability. As an OTC stock, there are also risks associated with limited liquidity and financial disclosure.